00:52 , Jan 18, 2019 |  BC Week In Review  |  Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035 is a...
20:50 , Jan 14, 2019 |  BC Extra  |  Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035 is a...
19:41 , Nov 21, 2018 |  BioCentury  |  Finance

Alphamab's cancer cash

Alphamab Oncology spun out from Suzhou Alphamab Co. Ltd. and raised more than $100 million in a series A round to advance multiple cancer biologics through clinical testing. Investors in the round, which closed on...
23:22 , Nov 16, 2018 |  BC Extra  |  Financial News

Alphamab Oncology raises more than $100M series A

Immuno-oncology company Alphamab Oncology (Cayman) raised over $100 million in a series A round to accelerate development of its biologics including lead product KN035. Advantech Capital, PAG, China Venture Capital Fund, OrbiMed Advisors, Heritage Provider...
19:40 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Alphamab Oncology, 3DMed start Phase II of PD-L1 antibody in solid tumors

Alphamab Oncology (Suzhou, China) and 3D Medicines Corp. (Shanghai, China) began a Phase II trial of KN035 in previously-treated patients with locally advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma...
19:26 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Alphamab Oncology, 3DMed start Phase III for PD-L1 antibody in cholangiocarcinoma

Alphamab Oncology (Suzhou, China) and 3D Medicines Corp. (Shanghai, China) began a Phase III trial of KN035 plus gemcitabine and oxaliplatin to treat cholangiocarcinoma. The open-label, Chinese trial will enroll about 390 patients. The trial's...
17:49 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

FDA OKs U.S. trial for Alphamab Oncology's HER2 bispecific antibody

Alphamab Oncology (Suzhou, China) said it received clearance from FDA to begin a U.S. Phase I trial of KN026, a HER2 bispecific antibody. Alphamab Oncology Chairman and CEO Ting Xu said in a statement that...
18:16 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Alphamab's bispecific checkpoint antibody enters clinic in Australia, Chinese trials planned

Alphamab Oncology (Suzhou, China) started an Australian Phase I trial of KN046 to treat advanced solid tumors. Data are expected this quarter. Alphamab also said China's National Medical Products Administration (NMPA) approved an IND for...